Santen Pharmaceutical（SZD）株式概要参天製薬株式会社は、日本および海外で医薬品および医療機器の研究開発、製造、販売を行っている。 詳細SZD ファンダメンタル分析スノーフレーク・スコア評価6/6将来の成長1/6過去の実績4/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より57.8%で取引されている 収益は年間6.74%増加すると予測されています 過去1年間で収益は22.8%増加しました 2.17%の安定した配当金を支払う 同業他社や業界と比較して、良好な取引価格 アナリストらは、株価が20.3%上昇するだろうとほぼ一致している。 リスク分析リスクチェックの結果、SZD 、リスクは検出されなかった。すべてのリスクチェックを見るSZD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,166 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,166 investors already sharing narrativesYour Fair Value€Current Price€9.9514.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-15b352b2016201920222025202620282031Revenue JP¥352.0bEarnings JP¥45.1bAdvancedSet Fair ValueView all narrativesSanten Pharmaceutical Co., Ltd. 競合他社Dermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.0bMerck KGaASymbol: XTRA:MRKMarket cap: €63.0bSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €3.3bSartoriusSymbol: XTRA:SRT3Market cap: €14.3b価格と性能株価の高値、安値、推移の概要Santen Pharmaceutical過去の株価現在の株価JP¥10.4052週高値JP¥11.9052週安値JP¥8.05ベータ0.241ヶ月の変化-9.57%3ヶ月変化21.64%1年変化21.64%3年間の変化26.83%5年間の変化-14.75%IPOからの変化167.08%最新ニュースReported Earnings • 13hFirst quarter 2027 earnings released: EPS: JP¥22.39 (vs JP¥17.33 in 1Q 2026)First quarter 2027 results: EPS: JP¥22.39 (up from JP¥17.33 in 1Q 2026). Revenue: JP¥69.0b (flat on 1Q 2026). Net income: JP¥7.19b (up 22% from 1Q 2026). Profit margin: 10% (up from 8.6% in 1Q 2026). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Declared Dividend • Jul 26Final dividend of JP¥21.00 announcedShareholders will receive a dividend of JP¥21.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 203%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 26% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 30Santen Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 06, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026Board Change • May 21High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. 1 highly experienced director. President, CEO & Representative Director Takeshi Ito is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026最新情報をもっと見るRecent updatesReported Earnings • 13hFirst quarter 2027 earnings released: EPS: JP¥22.39 (vs JP¥17.33 in 1Q 2026)First quarter 2027 results: EPS: JP¥22.39 (up from JP¥17.33 in 1Q 2026). Revenue: JP¥69.0b (flat on 1Q 2026). Net income: JP¥7.19b (up 22% from 1Q 2026). Profit margin: 10% (up from 8.6% in 1Q 2026). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Declared Dividend • Jul 26Final dividend of JP¥21.00 announcedShareholders will receive a dividend of JP¥21.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 203%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 26% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 30Santen Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 06, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026Board Change • May 21High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. 1 highly experienced director. President, CEO & Representative Director Takeshi Ito is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.お知らせ • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025Reported Earnings • Nov 11Second quarter 2025 earnings released: EPS: JP¥23.21 (vs JP¥23.45 in 2Q 2024)Second quarter 2025 results: EPS: JP¥23.21 (down from JP¥23.45 in 2Q 2024). Revenue: JP¥71.6b (down 2.4% from 2Q 2024). Net income: JP¥8.14b (down 8.2% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.Upcoming Dividend • Sep 20Upcoming dividend of JP¥17.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.1%).お知らせ • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: JP¥29.61 (vs JP¥27.93 in 1Q 2024)First quarter 2025 results: EPS: JP¥29.61 (up from JP¥27.93 in 1Q 2024). Revenue: JP¥74.8b (up 3.3% from 1Q 2024). Net income: JP¥10.6b (up 2.1% from 1Q 2024). Profit margin: 14% (in line with 1Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 22Now 20% undervaluedOver the last 90 days, the stock has risen 16% to €10.50. The fair value is estimated to be €13.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.5% per annum. Earnings are forecast to grow by 8.8% per annum over the same time period.Declared Dividend • Jul 11Final dividend of JP¥17.00 announcedShareholders will receive a dividend of JP¥17.00. Ex-date: 27th September 2024 Payment date: 2nd December 2024 Dividend yield will be 175%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 29% over the next 3 years, which should provide support to the dividend and adequate earnings cover.New Risk • Jul 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Board Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. COO, Corporate Officer & Director Rie Nakajima was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.Reported Earnings • May 10Full year 2024 earnings released: EPS: JP¥72.62 (vs JP¥38.60 loss in FY 2023)Full year 2024 results: EPS: JP¥72.62 (up from JP¥38.60 loss in FY 2023). Revenue: JP¥302.0b (up 8.2% from FY 2023). Net income: JP¥26.6b (up JP¥41.6b from FY 2023). Profit margin: 8.8% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.Upcoming Dividend • Mar 21Upcoming dividend of JP¥17.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.9%). In line with average of industry peers (2.4%).お知らせ • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥20.15 (vs JP¥15.50 in 3Q 2023)Third quarter 2024 results: EPS: JP¥20.15 (up from JP¥15.50 in 3Q 2023). Revenue: JP¥77.0b (up 8.7% from 3Q 2023). Net income: JP¥7.34b (up 23% from 3Q 2023). Profit margin: 9.5% (up from 8.4% in 3Q 2023). Revenue is expected to decline by 1.8% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year.お知らせ • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.Buy Or Sell Opportunity • Feb 01Now 20% undervaluedOver the last 90 days, the stock has risen 15% to €9.25. The fair value is estimated to be €11.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.4% per annum. Earnings are forecast to grow by 9.2% per annum over the same time period.お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024Reported Earnings • Nov 08Second quarter 2024 earnings released: EPS: JP¥24.11 (vs JP¥73.62 loss in 2Q 2023)Second quarter 2024 results: EPS: JP¥24.11 (up from JP¥73.62 loss in 2Q 2023). Revenue: JP¥73.4b (up 16% from 2Q 2023). Net income: JP¥8.87b (up JP¥37.6b from 2Q 2023). Profit margin: 12% (up from net loss in 2Q 2023). Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.Buying Opportunity • Nov 08Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.7%. The fair value is estimated to be €9.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.Upcoming Dividend • Sep 21Upcoming dividend of JP¥16.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 30 November 2023. The company is not currently making a profit and its cash payout ratio is 76%. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.5%).お知らせ • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023Buying Opportunity • Aug 07Now 21% undervaluedOver the last 90 days, the stock is up 5.3%. The fair value is estimated to be €10.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 04First quarter 2024 earnings released: EPS: JP¥27.94 (vs JP¥16.79 in 1Q 2023)First quarter 2024 results: EPS: JP¥27.94 (up from JP¥16.79 in 1Q 2023). Revenue: JP¥72.4b (up 11% from 1Q 2023). Net income: JP¥10.4b (up 56% from 1Q 2023). Profit margin: 14% (up from 10% in 1Q 2023). Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 2.8%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Board Change • Jul 25High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Outside Auditor Yaeko Hodaka was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023Reported Earnings • May 16Full year 2023 earnings released: JP¥38.58 loss per share (vs JP¥68.07 profit in FY 2022)Full year 2023 results: JP¥38.58 loss per share (down from JP¥68.07 profit in FY 2022). Revenue: JP¥279.0b (up 4.8% from FY 2022). Net loss: JP¥14.9b (down 155% from profit in FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance.お知らせ • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.Upcoming Dividend • Mar 23Upcoming dividend of JP¥16.00 per share at 2.9% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (2.8%).Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: JP¥15.51 (vs JP¥12.61 in 3Q 2022)Third quarter 2023 results: EPS: JP¥15.51 (up from JP¥12.61 in 3Q 2022). Revenue: JP¥70.9b (up 5.7% from 3Q 2022). Net income: JP¥5.98b (up 19% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.お知らせ • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.お知らせ • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥75.56 loss per share (vs JP¥17.42 profit in 2Q 2022)Second quarter 2023 results: JP¥75.56 loss per share (down from JP¥17.42 profit in 2Q 2022). Revenue: JP¥63.4b (flat on 2Q 2022). Net loss: JP¥28.7b (down JP¥35.7b from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 10Second quarter 2023 earnings released: JP¥73.61 loss per share (vs JP¥17.42 profit in 2Q 2022)Second quarter 2023 results: JP¥73.61 loss per share (down from JP¥17.42 profit in 2Q 2022). Revenue: JP¥63.4b (flat on 2Q 2022). Net loss: JP¥28.7b (down JP¥35.7b from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.Buying Opportunity • Nov 03Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €8.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.4% over the last 3 years. Earnings per share has declined by 25%. For the next 3 years, revenue is forecast to grow by 0.4% per annum. Earnings is also forecast to grow by 4.1% per annum over the same time period.Upcoming Dividend • Sep 22Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 30 November 2022. Payout ratio is a comfortable 48% but the company is paying out more than the cash it is generating. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (2.9%).Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: JP¥16.79 (vs JP¥18.36 in 1Q 2022)First quarter 2023 results: EPS: JP¥16.79 (down from JP¥18.36 in 1Q 2022). Revenue: JP¥65.5b (flat on 1Q 2022). Net income: JP¥6.66b (down 9.2% from 1Q 2022). Profit margin: 10% (down from 11% in 1Q 2022). Over the next year, revenue is expected to shrink by 2.7% compared to a 8.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year whereas the company’s share price has fallen by 22% per year.Board Change • Jul 31High number of new directorsIndependent Outside Director Noboru Kotani was the last director to join the board, commencing their role in 2022.お知らせ • May 12+ 4 more updatesSanten Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.Reported Earnings • May 11Full year 2022 earnings released: EPS: JP¥68.08 (vs JP¥17.09 in FY 2021)Full year 2022 results: EPS: JP¥68.08 (up from JP¥17.09 in FY 2021). Revenue: JP¥266.3b (up 6.7% from FY 2021). Net income: JP¥27.2b (up 299% from FY 2021). Profit margin: 10% (up from 2.7% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is expected to shrink by 1.9% compared to a 6.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Apr 08Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results on May 10, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (3.6%). In line with average of industry peers (2.6%).Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: JP¥12.62 (down from JP¥18.28 in 3Q 2021). Revenue: JP¥67.0b (up 6.6% from 3Q 2021). Net income: JP¥5.05b (down 31% from 3Q 2021). Profit margin: 7.5% (down from 12% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to stay flat compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Feb 10+ 1 more updateSanten Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year-Ending of March 2022Santen Pharmaceutical Co., Ltd. provided dividend guidance for the year ending March 2022. For the year, the company expects to pay dividend of ¥16.00 per share compared to JPY 14.00 per share paid a year ago.Reported Earnings • Nov 10Second quarter 2022 earnings released: EPS JP¥17.33 (vs JP¥19.09 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥63.8b (up 4.0% from 2Q 2021). Net income: JP¥6.93b (down 9.1% from 2Q 2021). Profit margin: 11% (down from 12% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 30 November 2021. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.7%).Reported Earnings • Aug 08First quarter 2022 earnings released: EPS JP¥18.47 (vs JP¥15.49 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2022 results: Revenue: JP¥65.0b (up 13% from 1Q 2021). Net income: JP¥7.38b (up 19% from 1Q 2021). Profit margin: 11% (in line with 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Board Change • Jul 31High number of new directorsStanding Corporate Auditor Hiroshi Isaka was the last director to join the board, commencing their role in 2020.Reported Earnings • May 14Full year 2021 earnings released: EPS JP¥17.10 (vs JP¥59.17 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: JP¥249.6b (up 3.3% from FY 2020). Net income: JP¥6.83b (down 71% from FY 2020). Profit margin: 2.7% (down from 9.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • May 11+ 1 more updateSanten Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 2022Santen Pharmaceutical Co., Ltd. provided dividend guidance for the Second quarter and full year ending March 2022. For the Second quarter, the company expects to pay dividends of ¥16.00 per share. For the year, the company expects to pay dividends of ¥16.00 per share.お知らせ • Apr 10+ 1 more updateSanten Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended March 31, 2021Santen Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the year ended March 31, 2021. For the period, the company now expects, on core basis, revenue of ¥249,000 million, core operating profit of ¥51,000, core net profit of ¥38,000 and basic core earnings per share of ¥98.13 compared to revenue of ¥235,000 million, core operating profit of ¥52,000, core net profit of ¥38,700 and basic core earnings per share of ¥97.67 for the same period expected previously. The company now expects, on IFRS basis, revenue of ¥249,000 million, operating profit of ¥249,000, net profit of ¥7,000 and basic earnings per share of ¥18.27 compared to revenue of ¥235,000 million, operating profit of ¥35,000, net profit of ¥23,000 and basic core earnings per share of ¥58.35 for the same period expected previously.Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 25 June 2021. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.0%).お知らせ • Mar 04Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2021 results on May 11, 2021Is New 90 Day High Low • Feb 13New 90-day low: €13.10The company is down 2.0% from its price of €13.30 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.40 per share.Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥18.29 (vs JP¥17.91 in 3Q 2020)The company reported a mediocre third quarter result with weaker revenues, although profit margins were flat and earnings improved. Third quarter 2021 results: Revenue: JP¥62.9b (down 1.1% from 3Q 2020). Net income: JP¥7.31b (up 2.2% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 07Revenue beats expectationsRevenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 3.8%, compared to a 2.3% growth forecast for the Pharmaceuticals industry in Germany.Is New 90 Day High Low • Nov 10New 90-day low: €13.90The company is down 10.0% from its price of €15.40 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.61 per share.Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectationsRevenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 2.7%, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Nov 08Second quarter 2021 earnings released: EPS JP¥19.09The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥61.3b (up 2.9% from 2Q 2020). Net income: JP¥7.63b (up 13% from 2Q 2020). Profit margin: 12% (up from 11% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 19New 90-day high: €17.70The company is up 20% from its price of €14.70 on 21 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.40 per share.Is New 90 Day High Low • Sep 18New 90-day high: €16.60The company is up 1.0% from its price of €16.50 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.64 per share.株主還元SZDDE PharmaceuticalsDE 市場7D3.0%1.7%2.2%1Y21.6%52.6%3.5%株主還元を見る業界別リターン: SZD過去 1 年間で52.6 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: SZD過去 1 年間で3.5 % の収益を上げたGerman市場を上回りました。価格変動Is SZD's price volatile compared to industry and market?SZD volatilitySZD Average Weekly Movement6.1%Pharmaceuticals Industry Average Movement5.4%Market Average Movement5.3%10% most volatile stocks in DE Market13.0%10% least volatile stocks in DE Market2.7%安定した株価: SZD 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SZDの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト18903,968Takeshi Itowww.santen.com/en参天製薬株式会社は、日本および海外で医薬品および医療機器の研究開発、製造、販売を行っています。同社の製品ポートフォリオには、プロスタグランジンF2a誘導体およびβアドレナリン受容体拮抗薬であるタフルプロスト／チモロールマレイン酸塩、緑内障および高眼圧症の治療薬として販売承認段階にあるプロスタグランジンF2a誘導体であるネタルスジルメシル酸塩およびラタノプロストなどがある。また、第3相臨床試験段階にあるプロスタグランジンアナログ点眼薬セペタプロスト、緑内障・高眼圧症治療薬として製造販売承認申請中のプロスタグランジンF2a誘導体乳剤ラタノプロストも提供している。さらに、春季性角結膜炎の治療薬として眼科用乳剤シクロスポリン、ドライアイの治療薬としてジクアホソルナトリウムを提供している。さらに、ドライアイ治療薬としてフェーズ1/2a段階にあるβ2受容体作動薬オロダテロール塩酸塩、フックス内皮角膜ジストロフィーおよびマイボーム腺機能不全の治療薬としてフェーズ2a段階にあるシロリムス点眼液を開発している；アレルギー性結膜炎の治療薬として承認申請中のヒスタミンH1受容体拮抗薬エピナスチン塩酸塩、近視治療薬として臨床第2/3相試験中の非選択的ムスカリン拮抗薬アトロピン硫酸塩、近視治療薬として臨床第2a相試験中の選択的ムスカリンM2拮抗薬AFDX0250BSがある。さらに、老眼治療薬として臨床第2a相試験中のウルソデオキシコール酸、眼瞼下垂症治療薬として臨床第3相試験中の直接作用型αアドレナリン受容体作動薬であるオキシメタゾリン塩酸塩を提供している。同社は1890年に設立され、大阪に本社を置いている。もっと見るSanten Pharmaceutical Co., Ltd. 基礎のまとめSanten Pharmaceutical の収益と売上を時価総額と比較するとどうか。SZD 基礎統計学時価総額€3.41b収益（TTM）€212.28m売上高(TTM)€1.60b16.1xPER（株価収益率2.1xP/SレシオSZD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SZD 損益計算書（TTM）収益JP¥291.84b売上原価JP¥119.23b売上総利益JP¥172.61bその他の費用JP¥133.94b収益JP¥38.68b直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）120.23グロス・マージン59.15%純利益率13.25%有利子負債／自己資本比率0%SZD の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.2%現在の配当利回り32%配当性向SZD 配当は確実ですか？SZD 配当履歴とベンチマークを見るSZD 、いつまでに購入すれば配当金を受け取れますか？Santen Pharmaceutical 配当日配当落ち日Sep 29 2026配当支払日Nov 30 2026配当落ちまでの日数51 days配当支払日までの日数113 daysSZD 配当は確実ですか？SZD 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/07 12:52終値2026/08/07 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Santen Pharmaceutical Co., Ltd. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Atsushi SekiBarclaysKoichi MameganoBofA Global ResearchHidemaru YamaguchiCitigroup Inc15 その他のアナリストを表示
Reported Earnings • 13hFirst quarter 2027 earnings released: EPS: JP¥22.39 (vs JP¥17.33 in 1Q 2026)First quarter 2027 results: EPS: JP¥22.39 (up from JP¥17.33 in 1Q 2026). Revenue: JP¥69.0b (flat on 1Q 2026). Net income: JP¥7.19b (up 22% from 1Q 2026). Profit margin: 10% (up from 8.6% in 1Q 2026). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Jul 26Final dividend of JP¥21.00 announcedShareholders will receive a dividend of JP¥21.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 203%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 26% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 30Santen Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 06, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026
Board Change • May 21High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. 1 highly experienced director. President, CEO & Representative Director Takeshi Ito is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
Reported Earnings • 13hFirst quarter 2027 earnings released: EPS: JP¥22.39 (vs JP¥17.33 in 1Q 2026)First quarter 2027 results: EPS: JP¥22.39 (up from JP¥17.33 in 1Q 2026). Revenue: JP¥69.0b (flat on 1Q 2026). Net income: JP¥7.19b (up 22% from 1Q 2026). Profit margin: 10% (up from 8.6% in 1Q 2026). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Jul 26Final dividend of JP¥21.00 announcedShareholders will receive a dividend of JP¥21.00. Ex-date: 29th September 2026 Payment date: 30th November 2026 Dividend yield will be 203%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 5.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 26% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 30Santen Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 06, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026
Board Change • May 21High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. 1 highly experienced director. President, CEO & Representative Director Takeshi Ito is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
お知らせ • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
お知らせ • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.
お知らせ • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025
お知らせ • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.
お知らせ • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.
お知らせ • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
Reported Earnings • Nov 11Second quarter 2025 earnings released: EPS: JP¥23.21 (vs JP¥23.45 in 2Q 2024)Second quarter 2025 results: EPS: JP¥23.21 (down from JP¥23.45 in 2Q 2024). Revenue: JP¥71.6b (down 2.4% from 2Q 2024). Net income: JP¥8.14b (down 8.2% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥17.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.1%).
お知らせ • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: JP¥29.61 (vs JP¥27.93 in 1Q 2024)First quarter 2025 results: EPS: JP¥29.61 (up from JP¥27.93 in 1Q 2024). Revenue: JP¥74.8b (up 3.3% from 1Q 2024). Net income: JP¥10.6b (up 2.1% from 1Q 2024). Profit margin: 14% (in line with 1Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 22Now 20% undervaluedOver the last 90 days, the stock has risen 16% to €10.50. The fair value is estimated to be €13.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.5% per annum. Earnings are forecast to grow by 8.8% per annum over the same time period.
Declared Dividend • Jul 11Final dividend of JP¥17.00 announcedShareholders will receive a dividend of JP¥17.00. Ex-date: 27th September 2024 Payment date: 2nd December 2024 Dividend yield will be 175%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 29% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
New Risk • Jul 04New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Board Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. COO, Corporate Officer & Director Rie Nakajima was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 10Full year 2024 earnings released: EPS: JP¥72.62 (vs JP¥38.60 loss in FY 2023)Full year 2024 results: EPS: JP¥72.62 (up from JP¥38.60 loss in FY 2023). Revenue: JP¥302.0b (up 8.2% from FY 2023). Net income: JP¥26.6b (up JP¥41.6b from FY 2023). Profit margin: 8.8% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥17.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.9%). In line with average of industry peers (2.4%).
お知らせ • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥20.15 (vs JP¥15.50 in 3Q 2023)Third quarter 2024 results: EPS: JP¥20.15 (up from JP¥15.50 in 3Q 2023). Revenue: JP¥77.0b (up 8.7% from 3Q 2023). Net income: JP¥7.34b (up 23% from 3Q 2023). Profit margin: 9.5% (up from 8.4% in 3Q 2023). Revenue is expected to decline by 1.8% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year.
お知らせ • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.
Buy Or Sell Opportunity • Feb 01Now 20% undervaluedOver the last 90 days, the stock has risen 15% to €9.25. The fair value is estimated to be €11.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.4% per annum. Earnings are forecast to grow by 9.2% per annum over the same time period.
お知らせ • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024
Reported Earnings • Nov 08Second quarter 2024 earnings released: EPS: JP¥24.11 (vs JP¥73.62 loss in 2Q 2023)Second quarter 2024 results: EPS: JP¥24.11 (up from JP¥73.62 loss in 2Q 2023). Revenue: JP¥73.4b (up 16% from 2Q 2023). Net income: JP¥8.87b (up JP¥37.6b from 2Q 2023). Profit margin: 12% (up from net loss in 2Q 2023). Revenue is expected to decline by 1.9% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
Buying Opportunity • Nov 08Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.7%. The fair value is estimated to be €9.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥16.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 30 November 2023. The company is not currently making a profit and its cash payout ratio is 76%. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.5%).
お知らせ • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
Buying Opportunity • Aug 07Now 21% undervaluedOver the last 90 days, the stock is up 5.3%. The fair value is estimated to be €10.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.5% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 04First quarter 2024 earnings released: EPS: JP¥27.94 (vs JP¥16.79 in 1Q 2023)First quarter 2024 results: EPS: JP¥27.94 (up from JP¥16.79 in 1Q 2023). Revenue: JP¥72.4b (up 11% from 1Q 2023). Net income: JP¥10.4b (up 56% from 1Q 2023). Profit margin: 14% (up from 10% in 1Q 2023). Revenue is expected to decline by 1.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 2.8%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Board Change • Jul 25High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Outside Auditor Yaeko Hodaka was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023
Reported Earnings • May 16Full year 2023 earnings released: JP¥38.58 loss per share (vs JP¥68.07 profit in FY 2022)Full year 2023 results: JP¥38.58 loss per share (down from JP¥68.07 profit in FY 2022). Revenue: JP¥279.0b (up 4.8% from FY 2022). Net loss: JP¥14.9b (down 155% from profit in FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance.
お知らせ • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥16.00 per share at 2.9% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (2.8%).
Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: JP¥15.51 (vs JP¥12.61 in 3Q 2022)Third quarter 2023 results: EPS: JP¥15.51 (up from JP¥12.61 in 3Q 2022). Revenue: JP¥70.9b (up 5.7% from 3Q 2022). Net income: JP¥5.98b (up 19% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.
お知らせ • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥75.56 loss per share (vs JP¥17.42 profit in 2Q 2022)Second quarter 2023 results: JP¥75.56 loss per share (down from JP¥17.42 profit in 2Q 2022). Revenue: JP¥63.4b (flat on 2Q 2022). Net loss: JP¥28.7b (down JP¥35.7b from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 10Second quarter 2023 earnings released: JP¥73.61 loss per share (vs JP¥17.42 profit in 2Q 2022)Second quarter 2023 results: JP¥73.61 loss per share (down from JP¥17.42 profit in 2Q 2022). Revenue: JP¥63.4b (flat on 2Q 2022). Net loss: JP¥28.7b (down JP¥35.7b from profit in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
Buying Opportunity • Nov 03Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €8.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.4% over the last 3 years. Earnings per share has declined by 25%. For the next 3 years, revenue is forecast to grow by 0.4% per annum. Earnings is also forecast to grow by 4.1% per annum over the same time period.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 30 November 2022. Payout ratio is a comfortable 48% but the company is paying out more than the cash it is generating. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (2.9%).
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: JP¥16.79 (vs JP¥18.36 in 1Q 2022)First quarter 2023 results: EPS: JP¥16.79 (down from JP¥18.36 in 1Q 2022). Revenue: JP¥65.5b (flat on 1Q 2022). Net income: JP¥6.66b (down 9.2% from 1Q 2022). Profit margin: 10% (down from 11% in 1Q 2022). Over the next year, revenue is expected to shrink by 2.7% compared to a 8.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year whereas the company’s share price has fallen by 22% per year.
Board Change • Jul 31High number of new directorsIndependent Outside Director Noboru Kotani was the last director to join the board, commencing their role in 2022.
お知らせ • May 12+ 4 more updatesSanten Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.
Reported Earnings • May 11Full year 2022 earnings released: EPS: JP¥68.08 (vs JP¥17.09 in FY 2021)Full year 2022 results: EPS: JP¥68.08 (up from JP¥17.09 in FY 2021). Revenue: JP¥266.3b (up 6.7% from FY 2021). Net income: JP¥27.2b (up 299% from FY 2021). Profit margin: 10% (up from 2.7% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is expected to shrink by 1.9% compared to a 6.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 08Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results on May 10, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (3.6%). In line with average of industry peers (2.6%).
Reported Earnings • Feb 11Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: JP¥12.62 (down from JP¥18.28 in 3Q 2021). Revenue: JP¥67.0b (up 6.6% from 3Q 2021). Net income: JP¥5.05b (down 31% from 3Q 2021). Profit margin: 7.5% (down from 12% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to stay flat compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 10+ 1 more updateSanten Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year-Ending of March 2022Santen Pharmaceutical Co., Ltd. provided dividend guidance for the year ending March 2022. For the year, the company expects to pay dividend of ¥16.00 per share compared to JPY 14.00 per share paid a year ago.
Reported Earnings • Nov 10Second quarter 2022 earnings released: EPS JP¥17.33 (vs JP¥19.09 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥63.8b (up 4.0% from 2Q 2021). Net income: JP¥6.93b (down 9.1% from 2Q 2021). Profit margin: 11% (down from 12% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 30 November 2021. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.7%).
Reported Earnings • Aug 08First quarter 2022 earnings released: EPS JP¥18.47 (vs JP¥15.49 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2022 results: Revenue: JP¥65.0b (up 13% from 1Q 2021). Net income: JP¥7.38b (up 19% from 1Q 2021). Profit margin: 11% (in line with 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Board Change • Jul 31High number of new directorsStanding Corporate Auditor Hiroshi Isaka was the last director to join the board, commencing their role in 2020.
Reported Earnings • May 14Full year 2021 earnings released: EPS JP¥17.10 (vs JP¥59.17 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: JP¥249.6b (up 3.3% from FY 2020). Net income: JP¥6.83b (down 71% from FY 2020). Profit margin: 2.7% (down from 9.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • May 11+ 1 more updateSanten Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 2022Santen Pharmaceutical Co., Ltd. provided dividend guidance for the Second quarter and full year ending March 2022. For the Second quarter, the company expects to pay dividends of ¥16.00 per share. For the year, the company expects to pay dividends of ¥16.00 per share.
お知らせ • Apr 10+ 1 more updateSanten Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended March 31, 2021Santen Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the year ended March 31, 2021. For the period, the company now expects, on core basis, revenue of ¥249,000 million, core operating profit of ¥51,000, core net profit of ¥38,000 and basic core earnings per share of ¥98.13 compared to revenue of ¥235,000 million, core operating profit of ¥52,000, core net profit of ¥38,700 and basic core earnings per share of ¥97.67 for the same period expected previously. The company now expects, on IFRS basis, revenue of ¥249,000 million, operating profit of ¥249,000, net profit of ¥7,000 and basic earnings per share of ¥18.27 compared to revenue of ¥235,000 million, operating profit of ¥35,000, net profit of ¥23,000 and basic core earnings per share of ¥58.35 for the same period expected previously.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 25 June 2021. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.0%).
お知らせ • Mar 04Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2021 results on May 11, 2021
Is New 90 Day High Low • Feb 13New 90-day low: €13.10The company is down 2.0% from its price of €13.30 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €15.40 per share.
Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥18.29 (vs JP¥17.91 in 3Q 2020)The company reported a mediocre third quarter result with weaker revenues, although profit margins were flat and earnings improved. Third quarter 2021 results: Revenue: JP¥62.9b (down 1.1% from 3Q 2020). Net income: JP¥7.31b (up 2.2% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 07Revenue beats expectationsRevenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 3.8%, compared to a 2.3% growth forecast for the Pharmaceuticals industry in Germany.
Is New 90 Day High Low • Nov 10New 90-day low: €13.90The company is down 10.0% from its price of €15.40 on 12 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.61 per share.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectationsRevenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 2.7%, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Nov 08Second quarter 2021 earnings released: EPS JP¥19.09The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥61.3b (up 2.9% from 2Q 2020). Net income: JP¥7.63b (up 13% from 2Q 2020). Profit margin: 12% (up from 11% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 19New 90-day high: €17.70The company is up 20% from its price of €14.70 on 21 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.40 per share.
Is New 90 Day High Low • Sep 18New 90-day high: €16.60The company is up 1.0% from its price of €16.50 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.64 per share.
